When was Idel Therapeutics founded?

Idel Therapeutics was founded in 2025 and raised its 1st funding round 1 year after it was founded.

Where is Idel Therapeutics located?

Idel Therapeutics is headquartered in Dortmund, Germany.

Is Idel Therapeutics a funded company?

Idel Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Mar 17, 2026.

When was the latest funding round of Idel Therapeutics?

Idel Therapeutics' latest funding was a $***** Seed round on Mar 17, 2026, with participation from 4 investors. Its primary sector is Oncology. In Germany, the Oncology sector has seen $78.5M in funding in 2026 to date.

Where does Idel Therapeutics rank among its competitors?

Idel Therapeutics ranks 133rd amongst 319 active competitors, of which 112 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Idel Therapeutics, which secured $4.02M in Mar, 2026.

Idel Therapeutics - 2026 Company Profile, Funding & Competitors

Q: Who are the top competitors of Idel Therapeutics?

Idel Therapeutics' top competitors include Agios Pharmaceuticals, Abcellera Biologics and Beijing Jiakesi drug development. Among them, Idel Therapeutics secured the most recent funding round in March, 2026.

Idel Therapeutics is a seed company based in Dortmund (Germany), founded in 2025. It operates as a Developer of a synthetic shuttle for targeted drug delivery. Idel Therapeutics has raised $10.3M in funding from BioMedPartners. The company has 319 active competitors, including 112 funded and 62 that have exited. Its top competitors include companies like Agios Pharmaceuticals, Abcellera Biologics and Beijing Jiakesi drug development.

Company Details

Developer of a synthetic shuttle for targeted drug delivery. The platform facilitates direct cytosolic delivery of therapeutic payloads into tumor cells. It utilizes a pan-tumor shuttle mechanism for efficient intracellular delivery across cancer types. The platform overcomes limited membrane permeability for therapeutic proteins and enables access to intracellular targets.

Key Metrics

Founded Year

2025

Location

Dortmund, Germany

Stage

Seed

Total Funding

$10.3M in 1 round

Latest Funding Round

Seed, Mar 17, 2026, $*****

Investors

BioMedPartners & 3 more

Ranked

133^rd among 319 active competitors

Similar Companies

Agios Pharmaceuticals & 408 more

View Idel Therapeutics' full profile

Idel Therapeutics has raised a total funding of $10.3M over 1 round. Its latest funding round was a Seed round on Mar 17, 2026 for $*****. 4 investors participated in its latest round. Idel Therapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Idel Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 17, 2026	1549043	Seed	3584078	1345105	7579991	1998922

Access funding benchmarks and valuations. Sign up today!

View details of Idel Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Idel Therapeutics include Agios Pharmaceuticals, Abcellera Biologics and Beijing Jiakesi drug development. Here is the list of Top 10 competitors of Idel Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	72/100
2nd	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	67/100
3rd	Beijing Jiakesi drug development 2015, Beijing (China), Public	Developer of small molecule based therapeutics for cancer treatment	$55M	Qiming Venture Partners, Lilly Asia Ventures ... & 3 others	67/100
4th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 8 others	64/100
5th	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	62/100
6th	FoRx Therapeutics 2019, Basel (Switzerland), Series A	Developer of compounds for treating cancer	$60.8M	Omega Funds, Novartis Venture Fund & 5 others	62/100
7th	Lyell Immunopharma 2018, San Francisco (United States), Public	Developer of CAR- T therapy for cancer treatment	$493M	Sahsen Ventures, GSK & 5 others	60/100
8th	Candel Therapeutics 1999, United States, Public	Developer of viral immunotherapies for the treatment of cancer	$81.6M	PBM Capital, B. Riley Wealth Management & 4 others	59/100
9th	GigaGen 2011, San Francisco (United States), Acquired	Developer of T-cell and antibody-based therapeutics	$36.1M	Claremont Creek Ventures, DOE & 5 others	59/100
10th	Black Diamond Therapeutics 2017, Cambridge (United States), Public	Developing MasterKey therapies to defeat cancer resistance and improve patient lives	$207M	Boxer Capital, RA Capital Management & 19 others	59/100
133rd	Idel Therapeutics 2025, Dortmund (Germany), Seed	Developer of a synthetic shuttle for targeted drug delivery	$10.3M	BioMedPartners, NRW.Venture & 2 others	34/100